Is axillary dissection unnecessary in patients with a positive sentinel lymph node?

Breast Cancer

Volumn 19, Issue 4, 2012, Pages 279-281

  Noguchi, Masakuni ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

Axillary lymph node dissection; Breast cancer; Micrometastases; Sentinel lymph node biopsy; Z 0011 trial

Indexed keywords

AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; MASTECTOMY; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; SENTINEL LYMPH NODE BIOPSY; TUMOR VOLUME; AXILLA; BREAST TUMOR; EDITORIAL; FEMALE; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEGMENTAL MASTECTOMY;

AXILLA; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPH NODE EXCISION; MASTECTOMY, SEGMENTAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SENTINEL LYMPH NODE BIOPSY;

EID: 84876434852     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-012-0351-4     Document Type: Review

References (24)

1. Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569-75.
2. Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252:426-32.
3. Morrow M, Giuliano AE. To cut is to cure: can we really apply Z11 in practice? Ann Surg Oncol. 2011;18:2413-15.
4. Noguchi M, Miwa K, Michigishi T, Yokoyama K, Nishijima H, Takanaka T, et al. The role of axillary lymph node dissection in breast cancer management. Breast Cancer. 1997;4:143-53.
5. Fisher B, Redmond C, Fisher ER, Bauer M, Wolmark N, Wickerham DL, et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med. 1985;312:674-81. (Pubitemid 15134703)
6. Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347:567-75.
7. Giuliano AE, Dale PS, Turner RR, Morton DL, Evans SW, Krasne DL. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg. 1995;222:394-401.
8. Cserni G, Gregori D, Merletti F, Sapino A, Mano MP, Ponti A, et al. Meta-analysis of non-sentinel node metastases associated with micrometastatic sentinel nodes in breast cancer. Br J Surg. 2004;91:1245-52. (Pubitemid 39331448)
9. Fletcher GH. Clinical dose of response curves of human malignant epithelial tumors. Br J Radiol. 1973;46:1-6.
10. Fletcher GH. Subclinical disease. Cancer. 1984;53:1274-84. (Pubitemid 14198884)
11. Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J Natl Cancer Inst. 2006;98:599-609. (Pubitemid 43904843)
12. Naik AM, Fey J, Gemignani M, Heerdt A, Montgomery L, Petrek J, et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection. A follow-up study of 4008 procedures. Ann Surg. 2004;240:462-71. (Pubitemid 39121340)
13. Galimberti V, Botteri E, Chifu C, Gentilini O, Luini A, Intra M, et al. Can we avoid axillary dissection in the micrometastatic sentinel node in breast cancer? Breast Cancer Res Treat. 2011;131:819-25.
14. Hwang RF, Gonzalez-Angulo AM, Yi M, Buchholz TA, Meric-Bernstam F, Kuerer HM, et al. Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection. Cancer. 2007;110:723-30. (Pubitemid 47257646)
15. Bilimoria KY, Bentrem DJ, Hansen NM, Bethke KP, Rademaker AW, Ko CY, et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol. 2009;27:2946-53.
16. Gnant M, Harbeck N, Thomssen C. St Gallen 2011: summary of the consensus discussion. Breast Care. 2011;2011(6):136-41.
17. Straver ME, Meijnen P, van Tienhoven G, van de Velde CJH, Mansel RE, Bogaerts J, et al. Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial. Ann Surg Oncol. 2010;17:1854-61.
18. Galimberti V. International Breast Cancer Study Group Trial of sentinel node biopsy. J Clin Oncol. 2006;24:210-1. (Pubitemid 46630516)
19. Cody HS III, Houssami N. Axillary management in breast cancer: What's new for 2012? The Breast 2012. doi: 10.1016/j.breast.2012.01.0011.
20. Noguchi M, Inokuchi M, To Z. Complement of peritumoral and subareolar injection in breast cancer sentinel lymph node biopsy. J Surg Oncol. 2009;100:100-5.
21. Noguchi M. Avoidance of axillary lymph node dissection in selected patients with node-positive breast cancer. EJSO. 2008;34:129-34.
22. McGhan LJ, Dueck AC, Gray RI, Wasif N, Mccullough AE, Pockaj BA. The changing landscape of axillary surgery: which breast cancer patients may still benefit from complete axillary lymph node dissection? J Surg Oncol. 2011. doi: 10.1002/jso.22131.
23. Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927-33.
24. Takei H, Kurosumi M, Yoshida T, Ishikawa Y, Hayashi Y, Ninomiya J, et al. Axillary lymph node dissection can be avoided in women with breast cancer with intraoperative, false-negative sentinel lymph node biopsy. Breast Cancer. 2010;17:9-16.